Get started
Sanofi S.A. (SAN.pa) bearish scenario:The technical figure Channel Up can be found in the daily chart in the French company Sanofi S.A. (SAN.pa). Sanofi S.A. is a French multinational pharmaceutical and healthcare company. Sanofi engages in the research and development, manufacturing and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines (it is the world's largest producer of the last through its subsidiary Sanofi Pasteur). The Channel Up broke through the support line on 24/01/2023. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 26 days towards 86.54 EUR. According to experts, your stop-loss order should be placed at 92.90 EUR if you decide to enter this position. French drugmaker Sanofi SA plans to launch a drug for rare bleeding disorder hemophilia A this year, Chief Executive Officer Paul Hudson told CNBC in an interview last week. The U.S. Food and Drug Administration last year accepted the marketing application for the therapy, which is being developed in collaboration with Swedish drugmaker Sobi, and is expected to decide on an approval status by Feb. 28. Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. About 400 babies are born with this condition every year, although the exact number of people affected is not known, according to government data. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:SANShort
by legacyFXofficial
Key levels for SANOFIThe algorithm is showing a very profitable pattern in SANOFI. First, if the price breaks up we have a clear rally until the top of the channel with a tight stop loss slightly below the break point. On the other hand, if the market is moving down, we should see a break to the downside of the channel, then an easy break of the support and the blue line would be the last support before we see a major correction to 83$, where 3 different patterns are pointing out as a clear support area where demand will come back. Good luck!
EURONEXT:SAN
by TopChartPatterns
Double bottom in Credit AgricoleThe algorithm shows an opportunity to buy credit agricole if the double bottom pattern breaks. The double bottom pattern is a bullish reversal pattern that appears on a chart as two distinct bottoms at roughly the same price level, separated by a peak in between. The pattern is formed when the price of an asset falls to a support level, bounces back up, falls back down to the same support level, and then bounces back up again. This pattern is considered bullish because it suggests that the asset's price may be about to start rising again after a period of decline. One way to trade the double bottom pattern is to wait for the price to break above the peak that separates the two bottoms. This is known as the "breakout." Once the price breaks above the peak, it is a signal to buy the asset. Some traders may also set a stop-loss order below the second bottom, to limit their potential losses in case the price does not continue to rise. So, a possibility is to wait the break of 10,2 level and look to sell in the next area where volume increase and we also find supports & resistances (11,50€). A break of the small black line could also be a great point to buy, but it's not a confirmation of the larger double bottom pattern.
EURONEXT:ACALong
by TopChartPatterns
Rising triangle in anticipation of accelerated approval of FDAPharming has received acceptance from both the EMA and FDA for the accelerated review of leniolisib. The new drug is anticipated to generate significantly more revenue compared to its current profitable drug Ruconest. While the company has been profitable for the past years, it needed to find new sources of income to be able to grow the value of the company. The end of 23Q1 will be crucial for shareholders, who would love to see acceptance from both EMA and FDA. Targets of 3-5 euro per share are not out of the question. A big spike can be expected, as a lot of people are expected to jump on this ship in case of approval. Based on the rising triangle pattern that has been forming since June 22, the theoretical price target would be 1.90 euro, with a breakout before March 8. For now we would look at reaching prior highs. Target 1: 1.50 euro Target 2: 1.635 euro Target 3: 1.90 euro
EURONEXT:PHARMLong
by Ntooj
Legrand (LR.pa) bearish scenario:The technical figure Channel Up can be found in the daily chart of the French company Legrand (LR.pa). Legrand is a French industrial group. It is one of the world leaders in electrical and digital building infrastructures and connected solutions. Legrand is established in 90 countries and its products are distributed in nearly 180. It generates 85% of its sales internationally. The group has expanded its product range in sustainable development and energy saving technologies, and has developed new products for EV charging/electric vehicles, lighting control and datacenters. The Channel Up broke through the support line on 23/12/2022. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 17 days towards 71.80 EUR. Your stop-loss order, according to experts, should be placed at 85.88 EUR if you decide to enter this position. Legrand, a world leader in electrical, digital infrastructure and connected solutions, has announced its acquisition of Encelium, an Ontario, Canada-based manufacturer of advanced commercial lighting controls. The acquisition of Encelium brand and products, which takes effect immediately, comes as part of Legrand's ongoing global strategy to further strengthen its position in the commercial lighting control sector. A leader in this category, Encelium is already an integral component within thousands of buildings, supporting the needs of occupants, tenants, and facilities managers through people-centric lighting and energy efficiency. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:LRShort
by legacyFXofficial
LVMH, retesting supports before a bounce?LVMH stock rallied and gained momentum after forming the Rounding Bottom pattern, now it is been trading in a downtrend channel, and, seems like it is forming it precisely because the price has been rejected by the upper side, so, if it confirmed to be valid, it will continue its way in the channel until the channel tests the last support, and when so, we'll see a great bounce to the previous levels before making new highs. NOTE: DYOR, stay cautious to place STOP LOSSes, and trade your own personality.
EURONEXT:MCShort
by Qasawa
Aegon N.V. (AGN.as) bullish scenario:The technical figure Ascending Triangle can be found in the daily chart in the Dutch company Aegon N.V. (AGN.as ). Aegon N.V. is a Dutch multinational life insurance, pensions and asset management company headquartered in The Hague, Netherlands. As of July 21, 2020, the company had 26,000 employees. Aegon is listed on the Euronext Amsterdam and is a constituent of the AEX index. The Ascending Triangle broke through the resistance line on 22/12/2022. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 23 days towards 5.064 EUR. Your stop-loss order, according to experts, should be placed at 4.488 EUR if you decide to enter this position. Aegon has completed two share buyback programs, one aimed at neutralizing the dilutive effect of the 2022 interim dividend paid in shares and the second to return EUR 300 million of surplus cash capital that was generated by the sale of Aegon’s Hungarian business to Vienna Insurance Group. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
EURONEXT:AGNLong
by legacyFXofficial
Sanofi found support at previous resistance.Sanofi - 30d expiry - We look to Buy a break of 88.01 (stop at 84.48) Previous resistance level of 88 broken. Our short term bias remains positive. Previous resistance, now becomes support at 88. 50 1day EMA is at 86.97. Support is located at 88 and should stem dips to this area. Daily signals are mildly bullish. Our profit targets will be 96.72 and 97.72 Resistance: 91.00 / 92.90 / 95.00 Support: 90.00 / 88.00 / 86.20 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
EURONEXT:SANLong
by Saxo
Selling AGS at break of recent low.Ageas - 30d expiry - We look to Sell a break of 40.19 (stop at 41.42) The primary trend remains bearish. We are trading at overbought extremes. A break of the recent low at 40.28 should result in a further move lower. Bearish divergence is expected to cap gains. A higher correction is expected. Our profit targets will be 37.11 and 36.51 Resistance: 42.65 / 43.40 / 44.60 Support: 41.60 / 40.30 / 39.20 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
EURONEXT:AGSShort
by Saxo